Pfizer's Newer Medicines Drive Q1 Revenue Growth

Pfizer reported strong revenue growth in its newer medicines during Q1 2026, offsetting a sharp decline in sales from its pandemic-era products. Operational revenue from launched and acquired products rose 22%, with notable growth in Padcev, Nurtec ODT, and oncology biosimilars. Despite weaker quarterly earnings, the company maintained its 2026 guidance.

By Tyler Bundy · TheStreet · May 6, 2026, 19:07 UTC

Tickers: $PFE

Topics: Covid-19 Earnings Pharmaceuticals Portfolio Diversification

Read the full article at TheStreet

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC
Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC